Immunology

Infliximab Biosimilar Maintains Remission, Trough Levels After Switch in IBD

September 3rd 2026

By Skylar Jeremias

A Japanese study found high remission and continuation rates, plus non-inferior trough levels, after patients with IBD were switched to the infliximab biosimilar CT-P13.

Biosimilars Round Up: July 2026

August 4th 2026

By Sabrina McCrear

Congress advances biosimilar bills as new data emerge on romosozumab, tirzepatide, and ustekinumab biosimilar development.

Eculizumab Biosimilar Shows Durable Benefit in Long-Term aHUS

July 29th 2026

By Pearl Steinzor

A 50-patient study found sustained platelet recovery and low thrombotic microangiopathy rates through 52 weeks of biosimilar therapy, with favorable safety.

Positioning Biosimilar Ustekinumab Early Reduces Burden on Spain's National Health System

June 26th 2026

By Skylar Jeremias

Early use of ustekinumab biosimilars in Spain shows cost-effective Crohn disease care, boosting QALYs and cutting NHS spend—insights for Europe.

FDA Approves Immgolis and Immgolis Intri as First Biosimilars to Golimumab Reference Products for RA and UC

June 8th 2026

By Kennedy Ferruggia

FDA approval clears interchangeable golimumab biosimilars for rheumatoid arthritis and ulcerative colitis, promising lower-cost TNF therapy.

Golimumab Biosimilar Matches Reference Drug in Year-Long RA Trial

March 19th 2026

By Skylar Jeremias

One-year trial shows AVT05 golimumab biosimilar matches Simponi in rheumatoid arthritis, including switching, with comparable safety and immunogenicity outcomes.

Switching to Biosimilar Etanercept Shows No Impact on Efficacy, Safety Across 18 Trials

March 16th 2026

By Skylar Jeremias

Real-world evidence shows switching between etanercept products and etanercept biosimilars preserves efficacy and safety, easing concerns and highlighting nocebo challenges.

Omalizumab Biosimilar Entry Linked to Expanded Patient Access, Reduced Spending

February 26th 2026

By Skylar Jeremias

Budget impact analysis finds omalizumab biosimilars in Europe could cut payer costs by €641M in 5 years, expanding access and driving major omalizumab savings.

Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 3rd 2026

By Skylar Jeremias

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Eye on Pharma: Global Approvals, Launches, and Strategic Partnerships

January 12th 2026

By Skylar Jeremias